Citigroup Inc Monte Rosa Therapeutics, Inc. Transaction History
Citigroup Inc
- $190 Billion
- Q1 2025
A detailed history of Citigroup Inc transactions in Monte Rosa Therapeutics, Inc. stock. As of the latest transaction made, Citigroup Inc holds 31,114 shares of GLUE stock, worth $140,324. This represents 0.0% of its overall portfolio holdings.
Number of Shares
31,114
Previous 44,883
30.68%
Holding current value
$140,324
Previous $311,000
53.7%
% of portfolio
0.0%
Previous 0.0%
Shares
15 transactions
Others Institutions Holding GLUE
# of Institutions
107Shares Held
53.4MCall Options Held
69.1KPut Options Held
22.4K-
Nea Management Company, LLC Timonium, MD7.69MShares$34.7 Million3.39% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD6.64MShares$30 Million0.0% of portfolio
-
Bvf Inc San Francisco, CA5.66MShares$25.5 Million1.15% of portfolio
-
Versant Venture Management, LLC San Francisco, CA5.65MShares$25.5 Million54.61% of portfolio
-
Baker Bros. Advisors LP New York, NY4.92MShares$22.2 Million0.27% of portfolio
About Monte Rosa Therapeutics, Inc.
- Ticker GLUE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,713,900
- Market Cap $211M
- Description
- Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing prot...